Salmonella enterica Serovar Enteritidis core O Polysaccharide conjugated to H:g,m Flagellin as a candidate vaccine for protection against invasive infection with S. Enteritidis

Infection and Immunity

Volumn 79, Issue 10, 2011, Pages 4240-4249

  Simon, Raphael ^a,b   Tennant, Sharon M ^a,b   Wang, Jin Y ^a,b   Schmidlein, Patrick J ^a,b   Lees, Andrew ^d   Ernst, Robert K ^c   Pasetti, Marcela F ^a,b   Galen, James E ^a,b   Levine, Myron M ^a,b  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

^d Fina BioSolutions   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLAGELLIN; IMMUNOGLOBULIN G; LIPOPOLYSACCHARIDE; MONOMER; POLYMER; SALMONELLOSIS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; BACTEREMIA; CONTROLLED STUDY; DRUG CONJUGATION; DRUG EFFICACY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; MACROPHAGE; MOLECULAR WEIGHT; MORTALITY; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; SALMONELLA ENTERICA; SALMONELLA ENTERITIDIS; TREATMENT DURATION;

ANIMALS; ANIMALS, OUTBRED STRAINS; ANTIBODIES, BACTERIAL; CELL LINE; FEMALE; FLAGELLIN; HUMANS; IMMUNIZATION; IMMUNOCONJUGATES; IMMUNOGLOBULIN G; MACROPHAGES; MICE; MICE, INBRED BALB C; O ANTIGENS; OPSONIN PROTEINS; PHAGOCYTOSIS; SALMONELLA ENTERITIDIS; SALMONELLA INFECTIONS, ANIMAL; SALMONELLA VACCINES;

EID: 80855127606     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.05484-11     Document Type: Article

References (73)

1. Andersen-Nissen, E., K. D. Smith, R. Bonneau, R. K. Strong, and A. Aderem. 2007. A conserved surface on Toll-like receptor 5 recognizes bacterial flagellin. J. Exp. Med. 204:393-403.
2. Bates, J. T., A. H. Graff, J. P. Phipps, J. M. Grayson, and S. B. Mizel. 2011. Enhanced antigen processing of flagellin fusion proteins promotes the antigen-specific CD8+ T cell response independently of TLR5 and MyD88. J. Immunol. 186:6255-6262.
3. + -T-cell responses generated during murine Salmonella enterica serovar Typhimurium infection are directed towards multiple epitopes within the natural antigen FliC. Infect. Immun. 73:7226-7235.
4. Berkley, J. A., et al. 2005. Bacteremia among children admitted to a rural hospital in Kenya. N. Engl. J. Med. 352:39-47.
5. Brent, A. J., et al. 2006. Salmonella bacteremia in Kenyan children. Pediatr. Infect. Dis. J. 25:230-236.
6. Brett, P. J., and D. E. Woods. 1996. Structural and immunological characterization of Burkholderia pseudomallei O-polysaccharide-flagellin protein conjugates. Infect. Immun. 64:2824-2828.
7. Chevance, F. F., and K. T. Hughes. 2008. Coordinating assembly of a bacterial macromolecular machine. Nat. Rev. Microbiol. 6:455-465.
8. Cookson, B. T., and M. J. Bevan. 1997. Identification of a natural T cell epitope presented by Salmonella-infected macrophages and recognized by T cells from orally immunized mice. J. Immunol. 158:4310-4319.
9. Cui, C., et al. 2010. Physical and chemical characterization and immunologic properties of Salmonella enterica serovar Typhi capsular polysaccharidediphtheria toxoid conjugates. Clin. Vaccine Immunol. 17:73-79.
10. Dagan, R., J. Poolman, and C. A. Siegrist. 2010. Glycoconjugate vaccines and immune interference: a review. Vaccine 28:5513-5523.
11. Darveau, R. P., and R. E. Hancock. 1983. Procedure for isolation of bacterial lipopolysaccharides from both smooth and rough Pseudomonas aeruginosa and Salmonella Typhimurium strains. J. Bacteriol. 155:831-838.
12. Datsenko, K. A., and B. L. Wanner. 2000. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc. Natl. Acad. Sci. U. S. A. 97:6640-6645.
13. Enwere, G., et al. 2006. Epidemiologic and clinical characteristics of community-acquired invasive bacterial infections in children aged 2-29 months in The Gambia. Pediatr. Infect. Dis. J. 25:700-705.
14. Gondwe, E. N., et al. 2010. Importance of antibody and complement for oxidative burst and killing of invasive nontyphoidal Salmonella by blood cells in Africans. Proc. Natl. Acad. Sci. U. S. A. 107:3070-3075.
15. Gonzalez-Fernandez, A., J. Faro, and C. Fernandez. 2008. Immune responses to polysaccharides: lessons from humans and mice. Vaccine 26:292-300.
16. Graham, S. M., A. L. Walsh, E. M. Molyneux, A. J. Phiri, and M. E. Molyneux. 2000. Clinical presentation of non-typhoidal Salmonella bacteraemia in Malawian children. Trans. R. Soc. Trop. Med. Hyg. 94:310-314.
17. Grossman, N., et al. 1987. Lipopolysaccharide size and distribution determine serum resistance in Salmonella Montevideo. J. Bacteriol. 169:856-863.
18. Heath, P. T. 1998. Haemophilus influenzae type b conjugate vaccines: a review of efficacy data. Pediatr. Infect. Dis. J. 17:S117-S122.
19. Heinrichs, D. E., J. A. Yethon, and C. Whitfield. 1998. Molecular basis for structural diversity in the core regions of the lipopolysaccharides of Escherichia coli and Salmonella enterica. Mol. Microbiol. 30:221-232.
20. Hirschfeld, M., Y. Ma, J. H. Weis, S. N. Vogel, and J. J. Weis. 2000. Repurification of lipopolysaccharide eliminates signaling through both human and murine Toll-like receptor 2. J. Immunol. 165:618-622.
21. Ibrahim, G. F., G. H. Fleet, M. J. Lyons, and R. A. Walker. 1985. Method for the isolation of highly purified Salmonella flagellins. J. Clin. Microbiol. 22:1040-1044.
22. Ikumapayi, U. N., et al. 2007. Molecular epidemiology of community-acquired invasive non-typhoidal Salmonella among children aged 2 29 months in rural Gambia and discovery of a new serovar, Salmonella enterica Dingiri. J. Med. Microbiol. 56:1479-1484.
23. Jimenez-Lucho, V. E., K. A. Joiner, J. Foulds, M. M. Frank, and L. Leive. 1987. C3b generation is affected by the structure of the O-antigen polysaccharide in lipopolysaccharide from Salmonellae. J. Immunol. 139:1253-1259.
24. Jones, G. W., L. A. Richardson, and D. Uhlman. 1981. The invasion of HeLa cells by Salmonella Typhimurium: reversible and irreversible bacterial attachment and the role of bacterial motility. J. Gen. Microbiol. 127:351-360.
25. Jorbeck, H. J., S. B. Svenson, and A. A. Lindberg. 1981. Artificial Salmonella vaccines: Salmonella Typhimurium O-antigen-specific oligosaccharide-protein conjugates elicit opsonizing antibodies that enhance phagocytosis. Infect. Immun. 32:497-502.
26. Kariuki, S., et al. 2006. Characterisation of community acquired non-typhoidal Salmonella from bacteraemia and diarrhoeal infections in children admitted to hospital in Nairobi, Kenya. BMC Microbiol. 6:101.
27. Kennedy, M., et al. 2004. Hospitalizations and deaths due to Salmonella infections, FoodNet, 1996-1999. Clin. Infect. Dis. 38(Suppl. 3):S142-S148.
28. Kingsley, R. A., et al. 2009. Epidemic multiple drug resistant Salmonella Typhimurium causing invasive disease in sub-Saharan Africa have a distinct genotype. Genome Res. 19:2279-2287.
29. Konadu, E., J. Shiloach, D. A. Bryla, J. B. Robbins, and S. C. Szu. 1996. Synthesis, characterization, and immunological properties in mice of conjugates composed of detoxified lipopolysaccharide of Salmonella Paratyphi A bound to tetanus toxoid with emphasis on the role of O acetyls. Infect. Immun. 64:2709-2715.
30. Konadu, E. Y., et al. 2000. Phase 1 and phase 2 studies of Salmonella enterica serovar Paratyphi A O-specific polysaccharide-tetanus toxoid conjugates in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect. Immun. 68:1529-1534.
31. Kossaczka, Z., et al. 1999. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect. Immun. 67:5806-5810.
32. Lees, A., B. L. Nelson, and J. J. Mond. 1996. Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate for use in protein-polysaccharide conjugate vaccines and immunological reagents. Vaccine 14:190-198.
33. Lees, A., G. Sen, and A. LopezAcosta. 2006. Versatile and efficient synthesis of protein-polysaccharide conjugate vaccines using aminooxy reagents and oxime chemistry. Vaccine 24:716-729.
34. Lepage, P., et al. 1987. Community-acquired bacteraemia in African children. Lancet i:1458-1461.
35. Levy, H., et al. 2008. PCR method to identify Salmonella enterica serovars Typhi, Paratyphi A, and Paratyphi B among Salmonella isolates from the blood of patients with clinical enteric fever. J. Clin. Microbiol. 46:1861-1866.
36. Liang-Takasaki, C. J., H. Saxen, P. H. Makela, and L. Leive. 1983. Complement activation by polysaccharide of lipopolysaccharide: an important virulence determinant of Salmonellae. Infect. Immun. 41:563-569.
37. Lin, F. Y., et al. 2001. The efficacy of a Salmonella Typhi Vi conjugate vaccine in two-to-five-year-old children. N. Engl. J. Med. 344:1263-1269.
38. Mai, N. L., et al. 2003. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. N. Engl. J. Med. 349:1390-1391.
39. Mandomando, I., et al. 2009. Invasive non-typhoidal Salmonella in Mozambican children. Trop. Med. Int. Health 14:1467-1474.
40. McSorley, S. J., B. T. Cookson, and M. K. Jenkins. 2000. Characterization of CD4+ T cell responses during natural infection with Salmonella Typhimurium. J. Immunol. 164:986-993.
41. Miao, E. A., E. Andersen-Nissen, S. E. Warren, and A. Aderem. 2007. TLR5 and Ipaf: dual sensors of bacterial flagellin in the innate immune system. Semin. Immunopathol. 29:275-288.
42. Micoli, F., et al. 2011. Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi. Vaccine 29:712-720.
43. Mizel, S. B., and J. T. Bates. 2010. Flagellin as an adjuvant: cellular mechanisms and potential. J. Immunol. 185:5677-5682.
44. Monsigny, M., C. Petit, and A. C. Roche. 1988. Colorimetric determination of neutral sugars by a resorcinol sulfuric acid micromethod. Anal. Biochem. 175:525-530.
45. Muthukkumar, S., and K. E. Stein. 2004. Immunization with meningococcal polysaccharide-tetanus toxoid conjugate induces polysaccharide-reactive T cells in mice. Vaccine 22:1290-1299.
46. O'Dempsey, T. J., et al. 1994. Importance of enteric bacteria as a cause of pneumonia, meningitis and septicemia among children in a rural community in The Gambia, West Africa. Pediatr. Infect. Dis. J. 13:122-128.
47. Ornellas, E. P., R. J. Roantree, and J. P. Steward. 1970. The specificity and importance of humoral antibody in the protection of mice against intraperitoneal challenge with complement-sensitive and complement-resistant Salmonella. J. Infect. Dis. 121:113-123.
48. Pace, D., A. J. Pollard, and N. E. Messonier. 2009. Quadrivalent meningococcal conjugate vaccines. Vaccine 27(Suppl. 2):B30-B41.
49. Palva, E. T., and P. H. Makela. 1980. Lipopolysaccharide heterogeneity in Salmonella Typhimurium analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis. Eur. J. Biochem. 107:137-143.
50. Pilishvili, T., et al. 2010. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J. Infect. Dis. 201:32-41.
51. Pollard, A. J., K. P. Perrett, and P. C. Beverley. 2009. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat. Rev. Immunol. 9:213-220.
52. Roantree, R. J., and L. A. Rantz. 1960. A study of the relationship of the normal bactericidal activity of human serum to bacterial infection. J. Clin. Invest. 39:72-81.
53. Samuel, G., and P. Reeves. 2003. Biosynthesis of O-antigens: genes and pathways involved in nucleotide sugar precursor synthesis and O-antigen assembly. Carbohydr Res. 338:2503-2519.
54. Sanders, C. J., et al. 2009. Induction of adaptive immunity by flagellin does not require robust activation of innate immunity. Eur. J. Immunol. 39:359-371.
55. Shafer, D. E., et al. 2000. Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) for use in proteinpolysaccharide conjugate vaccines and immunological reagents. II. Selective crosslinking of proteins to CDAP-activated polysaccharides. Vaccine 18:1273-1281.
56. Sigauque, B., et al. 2009. Community-acquired bacteremia among children admitted to a rural hospital in Mozambique. Pediatr. Infect. Dis. J. 28:108-113.
57. Simon, R., and C. E. Samuel. 2007. Activation of NF-kappaB-dependent gene expression by Salmonella flagellins FliC and FljB. Biochem. Biophys. Res. Commun. 355:280-285.
58. Simon, R., S. M. Tennant, J. E. Galen, and M. M. Levine. 2011. Mouse models to assess the efficacy of non-typhoidal Salmonella vaccines: revisiting the role of host innate susceptibility and routes of challenge. Vaccine 29:5094-5106.
59. Smith, K. D., et al. 2003. Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. Nat. Immunol. 4:1247-1253.
60. Strindelius, L., L. Degling Wikingsson, and I. Sjoholm. 2002. Extracellular antigens from Salmonella Enteritidis induce effective immune response in mice after oral vaccination. Infect. Immun. 70:1434-1442.
61. Strindelius, L., M. Filler, and I. Sjoholm. 2004. Mucosal immunization with purified flagellin from Salmonella induces systemic and mucosal immune responses in C3H/HeJ mice. Vaccine 22:3797-3808.
62. Svenson, S. B., and A. A. Lindberg. 1981. Artificial Salmonella vaccines: Salmonella Typhimurium O-antigen-specific oligosaccharide-protein conjugates elicit protective antibodies in rabbits and mice. Infect. Immun. 32:490-496.
63. Svenson, S. B., M. Nurminen, and A. A. Lindberg. 1979. Artificial Salmonella vaccines: O-antigenic oligosaccharide-protein conjugates induce protection against infection with Salmonella Typhimurium. Infect. Immun. 25:863-872.
64. Tennant, S. M., et al. 2010. Identification by PCR of non-typhoidal Salmonella enterica serovars associated with invasive infections among febrile patients in Mali. PLoS Negl. Trop. Dis. 4:e621.
65. Tennant, S. M., et al. 2011. Engineering and preclinical evaluation of attenuated nontyphoidal Salmonella strains serving as live oral vaccines and as reagent strains. Infect. Immun. 79:4175-4185.
66. Treanor, J. J., et al. 2010. Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults. Vaccine 28:8268-8274.
67. Vijay-Kumar, M., F. A. Carvalho, J. D. Aitken, N. H. Fifadara, and A. T. Gewirtz. 2010. TLR5 or NLRC4 is necessary and sufficient for promotion of humoral immunity by flagellin. Eur. J. Immunol. 40:3528-3534.
68. Vugia, D. J., et al. 2004. Invasive Salmonella infections in the United States, FoodNet, 1996-1999: incidence, serotype distribution, and outcome. Clin. Infect. Dis. 38(Suppl. 3):S149-S156.
69. Walsh, A. L., A. J. Phiri, S. M. Graham, E. M. Molyneux, and M. E. Molyneux. 2000. Bacteremia in febrile Malawian children: clinical and microbiologic features. Pediatr. Infect. Dis. J. 19:312-318.
70. Wang, B. Z., et al. 2008. Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J. Virol. 82:11813-11823.
71. Watson, D. C., J. B. Robbins, and S. C. Szu. 1992. Protection of mice against Salmonella Typhimurium with an O-specific polysaccharide-protein conjugate vaccine. Infect. Immun. 60:4679-4686.
72. Winter, S. E., et al. 2009. Contribution of flagellin pattern recognition to intestinal inflammation during Salmonella enterica serotype Typhimurium infection. Infect. Immun. 77:1904-1916.
73. Zhang, D., et al. 2004. A Toll-like receptor that prevents infection by uropathogenic bacteria. Science 303:1522-1526.